This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Adenosine A ₃ receptor (ADORA ₃)	<p><i>In vitro</i> studies identified a series of ADORA₃ antagonists that could help treat glioblastoma. Docking studies showed that N²-substituted pyrazolo[3,4-<i>d</i>]pyrimidines were highly potent and selective for ADORA₃ over ADORA₁ and ADORA_{2A}. In human glioma cells, the antagonists inhibited proliferation compared with that seen in vehicle control. Next steps could include testing the antagonists in animal models of brain cancer. Domain Therapeutics S.A. has DT0738, an ADORA antagonist, in preclinical testing to treat glaucoma.</p> <p>SciBX 3(18); doi:10.1038/scibx.2010.550 Published online May 6, 2010</p>	Patent and licensing status unavailable	<p>Taliani, S. <i>et al. J. Med. Chem.</i>; published online April 21, 2010; doi:10.1021/jm901785w</p> <p>Contact: Concettina La Motta, University of Pisa, Pisa, Italy e-mail: lamotta@farm.unipi.it</p>